Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Hubei Danao Pharmaceutical Co., Ltd.
WARNING LETTER
•Hubei Danao Pharmaceutical Co., Ltd.•August 4, 2017

Hubei Danao Pharmaceutical Co., Ltd. – FDA Warning Letter, Aug 4, 2017

Record Details

The FDA inspected Hubei Danjiangkou Danao Pharmaceutical Co., Ltd. from July 31 to August 4, 2017, identifying significant deviations from current good manufacturing practice (CGMP) for active pharmaceutical ingredients (API), rendering their API adulterated. The company's August 25, 2017, response was deemed inadequate.

Key violations include: 1. **Failure to validate manufacturing processes:** The company did not validate processes for numerous API batches prior to commercial distribution, lacked process qualification studies, and an ongoing program for monitoring process control. Batch records also lacked defined critical process parameters. 2. **Failure of quality unit to approve changes:** The firm failed to follow its change management program, implementing numerous undocumented changes without quality unit evaluation and approval, including product specifications, test methods, analytical equipment, and cleaning procedures. 3. **Failure to ensure scientifically sound test procedures:** Inadequate test procedures were observed, such as manual integration of a high-performance liquid chromatography test for API despite lacking peak resolution, without an approved protocol or quality oversight.

The FDA strongly recommended engaging a qualified CGMP consultant. The deviations are not an exhaustive list, and the company is responsible for investigation, root cause determination, and recurrence prevention. The firm was placed on Import Alert 66-40 on November 1, 2017. Failure to correct deviations may result in withheld approval of new applications and continued

Company
Hubei Danao Pharmaceutical Co., Ltd.
Inspection date
August 4, 2017
Product type
Drugs
Office
Center for Drug Evaluation and Research
Person
  • Francis Godwin (Director)
View Company Profile

ID · 97c6bfec-b615-4652-a731-a9abba95e3e6

Violation Codes5
21 U.S.C. 351(a)(2)(B)21 U.S.C. 356C(b)21 U.S.C. 381(a)(3)FD&C Act 501(a)(2)(B)FD&C Act 801(a)(3)

Full citation text and observation details available on the Dashboard.

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Hubei Danao Pharmaceutical Co., Ltd.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.